Patents by Inventor Lars Bjorck

Lars Bjorck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190079104
    Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 14, 2019
    Inventors: Lars BJÖRCK, Bertil CHRISTENSSON, Heiko HERWALD, Adam LINDER, Per AKESSON
  • Patent number: 10126312
    Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: November 13, 2018
    Assignee: Hansa Medical AB
    Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Patent number: 9784741
    Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: October 10, 2017
    Assignee: Hansa Medical AB
    Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Patent number: 9759720
    Abstract: It has been demonstrated that the level of HBP increases in individuals that have bacterial meningitis. Accordingly, the level of HBP in an individual can be used to determine whether or not an individual has bacterial meningitis.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: September 12, 2017
    Assignee: Hansa Medical AB
    Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Publication number: 20160252529
    Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 1, 2016
    Inventors: Lars BJÖRCK, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Patent number: 8889128
    Abstract: The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: November 18, 2014
    Assignee: Hansa Medical AB
    Inventors: Lars Björck, Mattias Collin, Arne Olsén, Rikard Holmdahl, Kutty Selva Nandakumar, Oonagh Shannon
  • Publication number: 20140187503
    Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.
    Type: Application
    Filed: December 2, 2013
    Publication date: July 3, 2014
    Applicant: Hansa Medical AB
    Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Publication number: 20140080754
    Abstract: It has been demonstrated that the level of HBP increases in individuals that have bacterial meningitis. Accordingly, the level of HBP in an individual can be used to determine whether or not an individual has bacterial meningitis.
    Type: Application
    Filed: September 23, 2011
    Publication date: March 20, 2014
    Applicant: HANSA MEDICAL AB
    Inventors: Lars Björck, Bertil Christensson, Adam Linder, Heiko Herwald, Per Åkesson
  • Publication number: 20140080925
    Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.
    Type: Application
    Filed: February 7, 2012
    Publication date: March 20, 2014
    Applicant: Hansa Medical AB
    Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Publication number: 20130252347
    Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 26, 2013
    Applicant: Hansa Medical AB
    Inventors: Lars Bjorck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Akesson
  • Patent number: 8518648
    Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: August 27, 2013
    Assignee: Hansa Medical AB
    Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Patent number: 8133483
    Abstract: The invention provides use of an IdeS polypeptide, or a polynucleotide encoding an IdeS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: March 13, 2012
    Assignee: Hansa Medical AB
    Inventors: Lars Björck, Rikard Holmdahl, Kutty Selva Nandakumar
  • Publication number: 20100303781
    Abstract: The invention provides use of an IdeS polypeptide, or a polynucleotide encoding an IdeS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.
    Type: Application
    Filed: June 8, 2006
    Publication date: December 2, 2010
    Inventors: Lars Björck, Rikard Holmdahl, Kutty Selva Nandakumar
  • Publication number: 20100305185
    Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.
    Type: Application
    Filed: June 12, 2008
    Publication date: December 2, 2010
    Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Publication number: 20100135981
    Abstract: The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.
    Type: Application
    Filed: December 12, 2007
    Publication date: June 3, 2010
    Applicant: Hansa Medical AB
    Inventors: Lars Bjorck, Mattias Collin, Arne Olsen, Rikard Holmdahl, Kutty Selva Nandakumar, Oonagh Shannon
  • Patent number: 7666582
    Abstract: A polypeptide isolated from S. pyogenes is described, having IgG cysteine protease activity. The protease is designated IdeS, Immunoglobulin G-degrading enzyme of S. pyogenes. A polypeptide comprises SEQ ID NO: 1 and variants and fragments thereof having IgG cysteine protease activity or the ability to generate an immune response against S. pyogenes in an individual. Polynucleotides encoding these polypeptides and the polypeptides may be used in generating an immune response in an individual. IdeS protease inhibitors may be used in the treatment of S. pyogenes infection.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: February 23, 2010
    Assignee: Hansa Medical Research AB
    Inventors: Ulrich Von Pawel-Rammingen, Bjorn Johansson, Lars Björck
  • Publication number: 20080085853
    Abstract: A nuclear delivery construct comprises (i) protein H or a fragment or derivative thereof that is capable of being targeted to the nucleus of a eukaryotic cell; and associated therewith (ii) one or more other components whose targeting to the nucleus of the eukaryotic cell is desired.
    Type: Application
    Filed: February 12, 2007
    Publication date: April 10, 2008
    Applicant: HANSA MEDICAL AB
    Inventors: Eugen Axcrona, Lars Bjorck, Inga-Maria Frick, Tomas Leandersson
  • Patent number: 7335355
    Abstract: A method of identifying an agent that enhances the anti-microbial activity of cationic anti-microbial peptides by blocking the inhibitory effects of the proteinase/glycosaminoglycan pathway, which method comprises: (i) providing, as a first component, a cationic anti-microbial peptide; (ii) providing, as a second component, bacteria; (iii) providing, as a third component, part of all of the components of a proteinase/glycosaminoglycan pathway such that the third component reduces the antimicrobial effect of the first component, for example, a glycosaminoglycan or bacteria or bacteria and a proteoglycan or a bacterial proteinase or a bacterial proteinase and a proteoglycan; (iv) contacting the first, second and third components with a test agent under conditions that would permit the killing of the bacteria by the antimicrobial agent in the absence of the third component, and that would permit the inhibition of the anti-microbial activity of the first component by the third component in the absence of the test
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: February 26, 2008
    Assignee: Hansa Medical AB
    Inventors: Lars Bjorck, Inga-Maria Frick, Artur Schmidtchen
  • Publication number: 20070237784
    Abstract: A polypeptide isolated from S. pyogenes is described, having IgG cysteine protease activity. The protease is designated IdeS, Immunoglobulin G-degrading enzyme of S. pyogenes. A polypeptide comprises SEQ ID NO: 1 and variants and fragments thereof having IgG cysteine protease activity or the ability to generate an immune response against S. pyogenes in an individual. Polynucleotides encoding these polypeptides and the polypeptides may be used in generating an immune response in an individual. IdeS protease inhibitors may be used in the treatment of S. pyogenes infection.
    Type: Application
    Filed: April 3, 2007
    Publication date: October 11, 2007
    Applicant: HANSA MEDICAL RESEARCH AB
    Inventors: Ulrich Von Pawel-Rammingen, Bjorn Johansson, Lars Bjorck
  • Publication number: 20070172471
    Abstract: A method for identifying an anti-streptococcal agent, comprises: (a) providing, as a first component, an isolated streptococcal M protein or a functional variant thereof; (b) providing, as a second component, isolated fibrinogen or a functional variant thereof; (b) providing, as a third component, an isolated ?2 integrin or a functional variant thereof; (d) contacting said components with a test substance under conditions that would permit the components to interact in the absence of the test substance; and (e) determining whether the test substance inhibits the interaction between the components; thereby to determine whether a test substance is an anti-streptococcal agent.
    Type: Application
    Filed: April 23, 2004
    Publication date: July 26, 2007
    Inventors: Lars Bjorck, Heiko Herwald, Matthias Morgelin, Wayne Russell, Anna Norrby-Teglund, Lennart Lindbom, Ulla Sollenberg, Henning Cramer, Hans Flodgaard